Fulgent Genetics Beheer
Beheer criteriumcontroles 2/4
De CEO Fulgent Genetics is Ming Hsieh, benoemd in May2016, heeft een ambtstermijn van 8.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.31M, bestaande uit 18.8% salaris en 81.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 28.52% van de aandelen van het bedrijf, ter waarde $ 155.91M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.7 jaar en 3.8 jaar.
Belangrijke informatie
Ming Hsieh
Algemeen directeur
US$5.3m
Totale compensatie
| Percentage CEO-salaris | 18.8% |
| Dienstverband CEO | 8.5yrs |
| Eigendom CEO | 28.5% |
| Management gemiddelde ambtstermijn | 4.7yrs |
| Gemiddelde ambtstermijn bestuur | 3.8yrs |
Recente managementupdates
Recent updates
Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
Sep 25Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
Sep 09Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio
Jul 17
Fulgent Genetics: Growth Is Returning
Jun 06Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package
May 10Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 07Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?
Mar 01Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Feb 21Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price
Jan 17Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Dec 14Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Aug 09Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 09Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital
Apr 19Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
Nov 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Oct 27Wait For Fulgent Genetics To Grow Up
Oct 13We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
Sep 19Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Jul 26Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
Jul 21Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Jun 04Fulgent Is Putting Its Cash Bonanza To Work
May 15These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics: Now The Going Could Get Much Tougher
Apr 10Fulgent Genetics: COVID Bolstered The Underlying Business
Mar 17Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business
Feb 27Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy
Feb 09Fulgent Genetics: Sell Volatility
Jan 26Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$165m |
| Jun 30 2024 | n/a | n/a | -US$163m |
| Mar 31 2024 | n/a | n/a | -US$166m |
| Dec 31 2023 | US$5m | US$1m | -US$168m |
| Sep 30 2023 | n/a | n/a | -US$64m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$5m | US$948k | US$143m |
| Sep 30 2022 | n/a | n/a | US$272m |
| Jun 30 2022 | n/a | n/a | US$392m |
| Mar 31 2022 | n/a | n/a | US$461m |
| Dec 31 2021 | US$6m | US$664k | US$507m |
| Sep 30 2021 | n/a | n/a | US$569m |
| Jun 30 2021 | n/a | n/a | US$493m |
| Mar 31 2021 | n/a | n/a | US$417m |
| Dec 31 2020 | US$248k | US$240k | US$214m |
| Sep 30 2020 | n/a | n/a | US$48m |
| Jun 30 2020 | n/a | n/a | US$3m |
| Mar 31 2020 | n/a | n/a | -US$459k |
| Dec 31 2019 | US$240k | US$240k | -US$411k |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$6m |
| Dec 31 2018 | US$240k | US$240k | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$5m |
| Jun 30 2018 | n/a | n/a | -US$6m |
| Mar 31 2018 | n/a | n/a | -US$5m |
| Dec 31 2017 | US$240k | US$240k | -US$3m |
Compensatie versus markt: De totale vergoeding ($USD 5.31M ) Ming } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.14M ).
Compensatie versus inkomsten: De vergoeding van Ming is gestegen terwijl het bedrijf verliesgevend is.
CEO
Ming Hsieh (68 yo)
8.5yrs
Tenure
US$5,309,167
Compensatie
Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 8.5yrs | US$5.31m | 28.52% $ 155.9m | |
| COO & President | 6.6yrs | US$1.79m | 1.42% $ 7.7m | |
| Chief Financial Officer | 8.8yrs | US$1.78m | 0.40% $ 2.2m | |
| Chief Scientific Officer & Laboratory Director | 8.2yrs | US$1.49m | 2.8% $ 15.3m | |
| General Counsel & Chief Privacy Officer | 2.5yrs | geen gegevens | geen gegevens | |
| VP of Operations & Compliance and GM of Houston Office | 4.1yrs | geen gegevens | geen gegevens | |
| Vice President of Business Development & Sales | 9.8yrs | geen gegevens | geen gegevens | |
| Vice President of Human Resources | 2.5yrs | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 4.7yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | 3.5yrs | geen gegevens | geen gegevens | |
| President & Chief Scientific Officer of Fulgent Pharma | 2yrs | geen gegevens | geen gegevens |
4.7yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van FLGT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 8.5yrs | US$5.31m | 28.52% $ 155.9m | |
| Independent Non-Employee Director | 1.8yrs | US$625.60k | 0.0039% $ 21.2k | |
| Independent Director | 5.3yrs | US$270.50k | 0.061% $ 333.4k | |
| Independent Non-Employee Director | 2.3yrs | US$268.50k | 0.0078% $ 42.6k |
3.8yrs
Gemiddelde duur
67yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van FLGT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).